2-chloro-1-morpholin-4-ylethaniminium chloride | 70379-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-chloro-1-morpholin-4-ylethaniminium chloride
• 英文别名: 2-chloro-1-morpholin-4-ylethanimine;hydrochloride
• CAS: 70379-45-2
• 化学式: C₆H₁₁ClN₂O*ClH
• 分子量: 199.08
• InChiKey: XPKBSYRYLIRWMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.96
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-1-morpholin-4-ylethaniminium chloride 、 对甲苯磺酰氯 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 N-(2-chloro-1-morpholin-4-ylethylidene)-4-methylbenzenesulfonamide
  参考文献：
  名称：

  [DE] GUANIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS BINDUNGSPARTNER FÜR 5-HT5-REZEPTOREN
  [EN] GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  [FR] COMPOSES DE GUANIDINE ET LEUR UTILISATION COMME ELEMENTS DE LIAISON POUR LES RECEPTEURS 5-HT5

  摘要：

  公开号：

  WO2005082871A3

文献信息

• Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors
  申请人：Netz Astrid

  公开号：US20070299074A1

  公开（公告）日：2007-12-27

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及通式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及胍化合物作为5-HT5受体的结合伴侣，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：Netz Astrid

  公开号：US20110237589A1

  公开（公告）日：2011-09-29

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物，其对应的对映异构体、顺反异构体和/或互变异构体以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗由5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors
  申请人：Netz Astrid

  公开号：US08481576B2

  公开（公告）日：2013-07-09

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：ABBVIE DEUTSCHLAND GMBH & CO. KG

  公开号：US20170037016A1

  公开（公告）日：2017-02-09

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.
• US8431604B2
  申请人：——

  公开号：US8431604B2

  公开（公告）日：2013-04-30